![Surviving-an-FDA-GCP-Inspection-500.jpg Surviving an FDA GCP Inspection](https://www.centerwatch.com/ext/resources/products/Surviving-an-FDA-GCP-Inspection-500.jpg?height=200&t=1605810958&width=200)
Home » The CenterWatch Monthly, March 2012
The CenterWatch Monthly, March 2012
March 1, 2012
Living in a post-M&A world of CROs
The CRO industry has been reshaped during the past year by a wave of acquisitions. Large-scale mergers, led by INC Research and inVentiv, have given mid-tier CROs the global scale needed to compete against their rivals for the biggest outsourcing opportunities. At the same time, the industry has consolidated as major CROs continue to make small, strategic acquisitions that can fill gaps in their…
Sites struggle with burden, blessing of multiple technologies
With pressure from sponsors and CROs to perform more efficiently and effectively, sites must depend on a variety of system requirements while keeping pace with evolving technology solutions. Sites typically adapt to the technology needs of sponsors and CROs, juggling multiple system requirements across multiple clinical trials, which results in…
Eye on Emergent
To reduce development risks and time before products come to market, Emergent BioSolutions uses an acquisition and licensing strategy to procure biodefense and commercial product candidates capable of stimulating a prophylactic or therapeutic immune response...
To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.
Upcoming Events
-
21Oct